Tofacitib Citrate API

Name	Tofacitib citrate
Chinese name	枸橼酸托法替布
Cas Number	540737-29-9
Source	India
Qualifications	-/-/-/-/-

The original manufacturer was Pfizer, which was approved by the FDA on November 6, 2012. Tofacitinib is the first JAK inhibitor approved by the FDA for the treatment of rheumatoid arthritis and the first oral anti-rheumatic drugs (DMARDs) approved for the treatment of rheumatoid arthritis in 10 years. It has been used in more than 50 worldwide Countries have been approved. It is different from those biological preparations that need to be used by injection, and it is easier to be accepted by doctors and patients. The target molecules of the existing immunosuppressive agents are widely distributed, so the selectivity is poor and it is prone to produce multi-directional toxicity. Tofacitinib is a newly developed JAK3 inhibitor, and its selective inhibitory effect is greatly improved. Since its launch, tofacitib's global sales have grown rapidly, with its 2018 sales of US$1.774 billion, making it a blockbuster drug. Some people think that the drug is comparable to "Yao Wang" Xiumile (adalimumab).

Hot Tags: tofacitib citrate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Pregabalin API, Fulvestrant API, Temozolomide API, Ranolazine API, Troxagliptin Succinate API, Adapalene API

• Previous: Erlotinib Hydrochloride API
• Next: Goserelin Acetate API